P

Prothena Corp
D

PRTA

17.480
USD
-0.86
(-4.69%)
Market Closed
Volume
18,387
EPS
0
Div Yield
0
P/E
-19
Market Cap
940,080,431
Related Instruments
    A
    ACAD
    -0.020
    (-0.11%)
    19.000 USD
    A
    ALNY
    31.19
    (13.13%)
    268.66 USD
    AMGN
    2.78
    (0.84%)
    335.22 USD
    A
    ARWR
    -1.160
    (-4.06%)
    27.410 USD
    C
    CRIS
    -0.60000
    (-11.05%)
    4.83000 USD
    GILD
    0.470
    (0.62%)
    76.510 USD
    I
    INCY
    -0.680
    (-1.05%)
    64.390 USD
    REGN
    13.14
    (1.22%)
    1,091.19 USD
    S
    SRPT
    1.650
    (1.16%)
    144.000 USD
    VRTX
    9.75
    (1.97%)
    505.40 USD
    More
News

Title: Prothena Corp

Sector: Healthcare
Industry: Biotechnology
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).